{"id":10190,"date":"2026-04-22T16:34:49","date_gmt":"2026-04-22T14:34:49","guid":{"rendered":"https:\/\/www.istitutopasteuritalia.it\/2026\/16\/high-grade-serous-ovarian-cancer-pin1-notch3-axis-identified-as-a-potential-new-therapeutic-target\/"},"modified":"2026-07-17T16:04:35","modified_gmt":"2026-07-17T14:04:35","slug":"high-grade-serous-ovarian-cancer-pin1-notch3-axis-identified-as-a-potential-new-therapeutic-target","status":"publish","type":"post","link":"https:\/\/www.istitutopasteuritalia.it\/en\/2026\/16\/high-grade-serous-ovarian-cancer-pin1-notch3-axis-identified-as-a-potential-new-therapeutic-target\/","title":{"rendered":"High-grade serous ovarian cancer: Pin1\/Notch3 axis identified as a potential new therapeutic target"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"10190\" class=\"elementor elementor-10190 elementor-9356\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e0d745a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"e0d745a\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-608700c\" data-id=\"608700c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-162678a elementor-widget elementor-widget-spacer\" data-id=\"162678a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c0380e8 elementor-widget elementor-widget-text-editor\" data-id=\"c0380e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h2 style=\"text-align: center;\">High-grade serous ovarian cancer: Pin1\/Notch3 axis identified as a potential new therapeutic target<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1df4612 elementor-widget elementor-widget-text-editor\" data-id=\"1df4612\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>High-grade serous ovarian cancer (HGSOC) is the most common histological subtype of ovarian cancer, and it represents one of the most lethal gynaecological malignancies. Current treatments mainly include primary debulking surgery following Platinum-based therapies even if neoadjuvant chemotherapy before surgery has become a valid option. Besides an initial good response, a higher percentage of HGSOC-bearing patients relapses, showing a platinum-resistance disease with dissemination in the peritoneum, the omentum and the organs located in the abdominal cavity. In this scenario, by using a multidisciplinary approach on HGSOC cells and primary tumors, we identified the Pin1-Notch3 axis as new potential biomarker predictive of Platinum-response, thus suggesting its targeting to counteract the potential therapeutic failure. Indeed, genetic Pin1 inhibition impinges on Notch3 protein stability and function, thus leading to a decreased HGSOC progression and metastatic spread, and finally resulting in Platinum re-sensitization both in vitro and in vivo.      Our study could allow the potential early stratification of patients into Platinum-sensitive and -resistant cohorts before clinical recurrence, thus supporting clinicians in selecting the most effective frontline treatment, finally resulting in therapeutic benefits and increased survival. <\/p><p><a href=\"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03658-x\"><strong>Click here for publication<\/strong> <\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5e8d7d9 elementor-widget elementor-widget-image\" data-id=\"5e8d7d9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t<figure class=\"wp-caption\">\n\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"750\" height=\"1000\" src=\"https:\/\/www.istitutopasteuritalia.it\/wp-content\/uploads\/2026\/04\/Foto-1_team-Checquolo-768x1024.jpg\" class=\"attachment-medium_large size-medium_large wp-image-10191\" alt=\"\" srcset=\"https:\/\/www.istitutopasteuritalia.it\/wp-content\/uploads\/2026\/04\/Foto-1_team-Checquolo-768x1024.jpg 768w, https:\/\/www.istitutopasteuritalia.it\/wp-content\/uploads\/2026\/04\/Foto-1_team-Checquolo-225x300.jpg 225w, https:\/\/www.istitutopasteuritalia.it\/wp-content\/uploads\/2026\/04\/Foto-1_team-Checquolo-359x479.jpg 359w\" sizes=\"(max-width: 750px) 100vw, 750px\" \/>\t\t\t\t\t\t\t\t\t\t\t<figcaption class=\"widget-image-caption wp-caption-text\">Prof. Saula Checquolo's research group<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>High-grade serous ovarian cancer: Pin1\/Notch3 axis identified as a potential new therapeutic target High-grade serous ovarian cancer (HGSOC) is the most common histological subtype of ovarian cancer, and it represents one of the most lethal gynaecological malignancies. Current treatments mainly include primary debulking surgery following Platinum-based therapies even if neoadjuvant chemotherapy before surgery has become &hellip;<\/p>\n","protected":false},"author":10,"featured_media":10191,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"give_campaign_id":0,"footnotes":""},"categories":[190],"tags":[],"class_list":["post-10190","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/posts\/10190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/comments?post=10190"}],"version-history":[{"count":10,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/posts\/10190\/revisions"}],"predecessor-version":[{"id":10764,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/posts\/10190\/revisions\/10764"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/media\/10191"}],"wp:attachment":[{"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/media?parent=10190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/categories?post=10190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.istitutopasteuritalia.it\/en\/wp-json\/wp\/v2\/tags?post=10190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}